Related Experiment Video
Updated: Jul 14, 2026
05:16
Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
Published on: August 4, 2021
[Relationship between three thrombophilic gene mutations and unexplained recurrent early spontaneous abortion]
Li Xu1, Xiao-man Liu, Hong-yan Zhang
1Reproductive Research Center, Qingdao Research Institute for Family Planning, Qingdao 266071, China.
Zhonghua Fu Chan Ke Za Zhi
|June 1, 2007
Summary
Genetic variations in the methylenetetrahydrofolate reductase (MTHFR) C677T gene are linked to unexplained recurrent early spontaneous abortion (URESA). Factor V and prothrombin gene mutations were not associated with URESA in this study population.
Area of Science:
- Reproductive Genetics
- Molecular Biology
- Thrombophilia
Context:
- Unexplained recurrent early spontaneous abortion (URESA) poses a significant challenge in reproductive medicine.
- Genetic factors, including gene polymorphisms, are increasingly recognized as potential contributors to pregnancy loss.
- Investigating specific gene mutations like MTHFR C677T, Factor V G1691A, and Prothrombin G20210A is crucial for understanding URESA pathogenesis.
Purpose:
- To investigate the association between methylenetetrahydrofolate reductase (MTHFR) C677T, factor V (FV) G1691A, and prothrombin (PT) G20210A gene polymorphisms and unexplained recurrent early spontaneous abortion (URESA).
Summary:
- A case-control study analyzed 112 URESA patients and 100 controls using PCR-RFLP.
- MTHFR C677T gene T/T genotype and T allele frequencies were significantly higher in URESA patients (P<0.01).
- Carriage of the MTHFR T/T genotype increased the risk of URESA (OR=2.8390). FV and PT G20210A mutations were absent in both groups.
Impact:
- The MTHFR C677T polymorphism is associated with URESA, suggesting a genetic predisposition.
- FV and PT G20210A mutations appear to have minimal or no role in URESA among Chinese women.
- Findings contribute to understanding the genetic underpinnings of recurrent pregnancy loss and may inform future diagnostic approaches.
More Related Videos
Related Concept Videos
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:49Probability Laws
Overview